

Press release
November 30, 2020

Interim report January – September 2020

Curasight A/S (“Curasight” or “the Company”) hereby publishes the interim report for the period January 1 – September 30, 2020. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.

Curasight’s CEO Ulrich Krasilnikoff comments:

“The Company’s recent financial injection paired up with our pioneering technology puts Curasight in an excellent position to realize our goal of being at the forefront of a paradigm shift in treating and diagnosing cancer. Together with the strong and broad pipeline of studies using Curasight’s technology, we are determined to generate long-term value to its shareholders.”

Third quarter, Q3 2020

- Net sales amounted to 0 (0) DKK
- Operating profit/loss amounted to -218,370 (-252,981) DKK
- Profit/loss before taxes amounted to -443,100 (-429,509) DKK
- Profit/loss for the period amounted to -345,618 (-335,017) DKK
- Total assets amounted to 68,720,255 (22,619,811) DKK
- Equity ratio amounted to 93.0 (82.0)
- Earnings per share amounted to -0,02 (-0.37*)

January – September, Q1 – Q3 2020

- Net sales amounted to 0 (0) DKK
- Operating profit/loss was -365,180 (-437,474) DKK
- Profit/loss before taxes amounted to -1,006,465 (-1,035,928) DKK
- Profit/loss for the period amounted to -785,043 (-808,024) DKK
- Total assets amounted to 68,720,255 (22,619,811) DKK
- Equity ratio amounted to 93.0 (82.0)
- Earnings per share amounted to -0,05 (-0.91*)

* Nom. Value per share changed in 2019 from DKK 1.00 to DKK 0.05

Highlights during the third quarter

- On September 2, Curasight announced that the Company had received approval for listing at Spotlight Stock Market. The Company also published the prospectus for the issue of units.
- On September 3, the subscription period for Curasight’s issue of units began.
- On September 9, CEO Ulrich Krasilnikoff and CSO Andreas Kjaer presented Curasight’s operations and future plans via a webcast on BioStock.
- On September 17, the subscription period for Curasight’s issue of units ended.
- On September 22, the Company announced that the initial part of the IPO of units was subscribed to approx. DKK 273 million (before issue costs), corresponding to a subscription ratio of approx. 835 percent. Curasight was provided with approx. DKK 32.7 million (before issue costs) and received approx. 1,700 new shareholders.
- On September 22, in addition to the IPO of units, the Company executed a directed issue of units at the same terms as in the IPO, which provided Curasight with an additional approx. DKK 14 million (before issue costs).
- In total, the Company raised approx. DKK 46.7 million (before issue costs).

Highlights after the period

- On October 7, Curasight announced that the Company had entered into an expansion of the agreement with TRT Innovations ApS, which ensures Curasight the right to broaden its activities within targeted radionuclide therapy in cancer.
- October 8 was the first day of trading in Curasight's shares and warrants of series TO 1 at Spotlight Stock Market.
- On October 22, the Canadian Intellectual Property Office announced that Curasight's Canadian patent application CA 2,903,261 was ready for allowance and that the patent would be issued. This patent application relates to Curasight's imaging technology relating to uTRACE[®] (imaging agent 68Ga-NOTA-AE105) and uses thereof until 2034.
- On November 11, Curasight initiated its pre-clinical study on therapy (uTREAT[®]) in brain cancer and signed a CRO-agreement.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
www.curasight.com

This information is such information as Curasight A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on November 30, 2020.

Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology provides improved diagnosis and risk stratification in multiple cancer types.